Your browser doesn't support javascript.
loading
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review.
Parrao, Diego; Lizana, Nemecio; Saavedra, Catalina; Larrañaga, Matías; Lindsay, Carolina B; San Francisco, Ignacio F; Bravo, Juan Cristóbal.
Affiliation
  • Parrao D; School of Medicine, University of O'Higgins, Rancagua 282000, Chile.
  • Lizana N; School of Medicine, University of O'Higgins, Rancagua 282000, Chile.
  • Saavedra C; School of Medicine, University of O'Higgins, Rancagua 282000, Chile.
  • Larrañaga M; Department of Urology, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile.
  • Lindsay CB; Research Department, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile.
  • San Francisco IF; Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Bravo JC; Department of Urology, Libertador Bernardo O'Higgins Regional Hospital, Rancagua 282000, Chile.
Curr Oncol ; 31(4): 2201-2220, 2024 04 12.
Article in En | MEDLINE | ID: mdl-38668066
ABSTRACT
Bladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health system associated with therapy. In this clinical scenario, strategies such as active surveillance have emerged that propose to manage low-risk BC with follow-up; however, due to the low evidence available, this is a strategy that is underutilized by clinicians. On the other hand, in the era of biomarkers, it is increasingly known how to use them as a tool in BC. Therefore, the aim of this review is to provide to clinical practitioners the evidence available to date on AS and the potential role of biomarkers in this therapeutic strategy in patients with low-grade/risk NMIBC. This is the first review linking use of biomarkers and active surveillance, including 29 articles.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Non-Muscle Invasive Bladder Neoplasms Limits: Humans Language: En Journal: Curr Oncol Year: 2024 Document type: Article Affiliation country: Chile

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Non-Muscle Invasive Bladder Neoplasms Limits: Humans Language: En Journal: Curr Oncol Year: 2024 Document type: Article Affiliation country: Chile